Vitamin pills mostly flopped against COVID, with two narrow exceptions

Vitamins were among the most heavily promoted products of the pandemic, sold on the promise of supporting immunity against COVID-19 and, later, easing long COVID. Whether any of that promise survives contact with randomised trial evidence is a question with real money and real health decisions attached. Earlier reviews existed, but trials kept publishing, so this updated review set out to evaluate whether any vitamin supplementation regimen prevents or helps manage COVID-19 or long COVID. Pooling the trials also allowed the authors to estimate effects on the hardest outcome of all, death from any cause.

The authors searched databases up to May 2023 for randomised clinical trials comparing vitamin supplementation against placebo or standard care for COVID-19 or long COVID. Overall, 37 articles were included: two addressed prevention of COVID-19 and long COVID, and 35 addressed COVID-19 management. The vitamins studied included multivitamins and vitamins A, B, C and D. Inverse-variance random-effects pooled analyses were run to estimate risk ratios for all-cause mortality between supplemented and non-supplemented people.

The effects of vitamin D on preventing COVID-19 and long COVID were contrasting, and no conclusion could be drawn on multivitamins, vitamin A or vitamin B for managing the disease. Vitamin C trials produced a few positive findings, but results were inconsistent across most outcomes; the exception was all-cause mortality, where the pooled risk ratio was 0.84. Vitamin D results were mixed on most fronts, including mortality, where benefit appeared only with regular administration, at a pooled risk ratio of 0.67. Despite these scattered positives, the authors describe the overall results as mostly contradictory.

This update lands on much the same verdict as the cautious end of earlier evidence: vitamins have not demonstrated consistent protection or treatment benefit against COVID-19. The authors suggest the variety in recruitment and treatment protocols across trials may explain why results contradict each other, and they call for better-designed studies to clarify any real effects. The mortality signals for vitamin C and regularly administered vitamin D are the findings most worth watching, but they sit inside an otherwise inconsistent evidence base. The gap between marketing and trial data remains wide.

If you bought vitamins during the pandemic hoping for protection, this is the sober accounting: across 37 trials, no vitamin showed consistent benefit for preventing or managing COVID-19 or long COVID. The isolated positive signals on death rates are intriguing rather than convincing, given how much the trials disagreed. For a healthy person deciding what to spend on, nothing in this evidence supports vitamins as a COVID defence, and that itself is useful to know.